- Home
- IOBT vs OMIC Comparison
IOBT vs OMIC Comparison
Compare IOBT & OMIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- OMIC
- Stock Information
- Founded
- IOBT 2014
- OMIC 2016
- Country
- IOBT Denmark
- OMIC United States
- Employees
- IOBT N/A
- OMIC 127
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- OMIC Medical/Dental Instruments
- Sector
- IOBT Health Care
- OMIC Health Care
- Exchange
- IOBT Nasdaq
- OMIC Nasdaq
- Market Cap
- IOBT 56.7M
- OMIC 49.9M
- IPO Year
- IOBT 2021
- OMIC 2021
- Fundamental
- Price
- IOBT $0.84
- OMIC $19.70
- Analyst Decision
- IOBT Strong Buy
- OMIC Hold
- Analyst Count
- IOBT 3
- OMIC 2
- Target Price
- IOBT $9.33
- OMIC $10.75
- AVG Volume (30 Days)
- IOBT 203.5K
- OMIC 21.3K
- Earning Date
- IOBT 03-04-2025
- OMIC 11-12-2024
- Dividend Yield
- IOBT N/A
- OMIC N/A
- EPS Growth
- IOBT N/A
- OMIC N/A
- EPS
- IOBT N/A
- OMIC N/A
- Revenue
- IOBT N/A
- OMIC $2,667,000.00
- Revenue This Year
- IOBT N/A
- OMIC $0.82
- Revenue Next Year
- IOBT N/A
- OMIC $252.64
- P/E Ratio
- IOBT N/A
- OMIC N/A
- Revenue Growth
- IOBT N/A
- OMIC 2.77
- 52 Week Low
- IOBT $0.66
- OMIC $5.34
- 52 Week High
- IOBT $1.89
- OMIC $23.41
- Technical
- Relative Strength Index (RSI)
- IOBT 45.71
- OMIC 48.55
- Support Level
- IOBT $0.77
- OMIC $19.25
- Resistance Level
- IOBT $0.95
- OMIC $19.90
- Average True Range (ATR)
- IOBT 0.08
- OMIC 0.32
- MACD
- IOBT -0.01
- OMIC 0.02
- Stochastic Oscillator
- IOBT 22.16
- OMIC 54.55
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About OMIC Singular Genomics Systems Inc.
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.